Organization
Vertex Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Vertex Pharmaceuticals, Inc.
... to ORKAMBI for these children. In other countries across the European Union, Vertex will now begin the country-by-country reimbursement process. "The innovative long-term agreements we ...
... On January 10, at 12 noon, at the Auditorium of the Vertex Building of the UPC, in Barcelona. This Wednesday, January 10, at 12:00 ...
... CF and beyond. At the J.P. Morgan Healthcare Conference Monday, Leiden said Vertex has a three-part strategy in business development. Vertex is aiming for assets ...
... www.vrtx.com The audio portion of management's remarks can be accessed live through Vertex's website, in the 'Investors' section under the 'News and Events' page. In ...
... call will also be available as a live and archived webcast on Vertex's website. About Vertex Vertex is a global biotechnology company that invests in ...
... Invisalign surged 33% from a year earlier in its most recent quarter. Vertex Pharmaceuticals, +103% Vertex’s stock has surged this year as its cystic-fibrosis drugs ...
... including Abilita Bio, Astellas, Department of Defense/Harvard, Gilead Sciences, Ono, Otsuka, Taiho, Vertex and one undisclosed partner. This year also saw several expansions of X-Chem's ...
... Business School in 2005. Prior to that, she was the President of Vertex Pharmaceuticals from 2000 until her retirement from that position in 2005, and ...
... resolutions at those five drugmakers, ICCR members requested reports from Pfizer and Vertex Pharmaceuticals about how efforts to curb U.S. drug costs could affect their ...
... that use the CRISPR/Cas9 technology. CTX001 represents the first gene-based treatment that Vertex exclusively licensed from CRISPR Therapeutics as part of the collaboration. For CTX001, ...
... it poured $105 million into a research collaboration with CRISPR Therapeutics. Now, Vertex is licensing the first CRISPR-based treatment to come out of the deal: ...
... ongoing in infants younger than one year old. Based on these results, Vertex plans to submit applications for ivacaftor in children ages 1 to 2 ...
... may be even scarcer in such life science and high-tech firms as Vertex Pharmaceuticals and LogMeIn that give the Seaport cachet as the "Innovation District." ...
... do not. And it's not just cancer, of course. Cystic fibrosis [drugmaker] Vertex vrtx has shown pretty remarkable advances there in treating that terrible disease. ...
... ongoing in infants younger than one year old. Based on these results, Vertex plans to submit applications for ivacaftor in children ages 1 to 2 ...
... and painful and debilitating sickle crises for sickle cell patients. About the CRISPR-Vertex Collaboration CTX001 is the first CRISPR/Cas9-based treatment to advance from a research ...
... trip to Boston. From their hotel they saw a building bearing the Vertex Pharmaceuticals logo, which is on the packaging of the Orkambi pills Mamie ...
... by a flap involving the Orkambi cystic fibrosis drug, sold by Vertex Pharmaceuticals Inc., of Boston. After months of talks during which the government initially ...
... a $21 million in Series B funding led by Redpoint Ventures and Vertex . [ts_bullet_primary] Noodle Partners , a New York firm that helps colleges ...
... fibrosis, that has not been approved for public funding in Canada. Vertex Pharmaceuticals Inc. is demanding negotiations with the provinces on a bulk deal for ...
... During a watchmaking year of rampant retro revivals, old Brit name Vertex has gone one step further and revives an entire brand. With rare ...
... and shareholders of Barracuda Networks, Inc. (NYSE:CUDA), Abraxas Petroleum Corporation (NASDAQ:AXAS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Incyte Corporation (NASDAQ:INCY), Forum Energy Technologies, Inc. (NYSE:FET), and S&P ...
... of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals is a great example of leveraging our platform to rapidly create ...
... If you want a Stock Review on SGMO, VRTX, ATHX, or AVEO then come over tohttp://dailystocktracker.com/register/and sign up for your free ...
... from birth," said David Gillen, M.D., Head of International Medical Affairs at Vertex. "This recommendation brings us closer to being able to help more people ...
Want to see the full history on Vertex Pharmaceuticals, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial